ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for default Register for Free to get streaming real-time quotes, interactive charts, live options flow, and more.

REGN Regeneron Pharmaceuticals Inc

1,094.99
12.88 (1.19%)
After Hours
Last Updated: 21:13:34
Delayed by 15 minutes
Share Name Share Symbol Market Type
Regeneron Pharmaceuticals Inc NASDAQ:REGN NASDAQ Common Stock
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  12.88 1.19% 1,094.99 1,088.92 1,100.00 1,100.08 1,079.0855 1,087.89 276,561 21:13:34

Statement of Changes in Beneficial Ownership (4)

18/05/2022 9:05pm

Edgar (US Regulatory)


FORM 4
[ ] Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).         
UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES
                                                                                  
OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response...
0.5
                      
Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940
                      

1. Name and Address of Reporting Person *

MURPHY ANDREW J
2. Issuer Name and Ticker or Trading Symbol

REGENERON PHARMACEUTICALS, INC. [ REGN ]
5. Relationship of Reporting Person(s) to Issuer (Check all applicable)

_____ Director                    _____ 10% Owner
__X__ Officer (give title below)    _____ Other (specify below)
EVP Research
(Last)          (First)          (Middle)

777 OLD SAW MILL RIVER ROAD
3. Date of Earliest Transaction (MM/DD/YYYY)

5/16/2022
(Street)

TARRYTOWN, NY 10591
(City)        (State)        (Zip)
4. If Amendment, Date Original Filed (MM/DD/YYYY)

 
6. Individual or Joint/Group Filing (Check Applicable Line)

_X _ Form filed by One Reporting Person
___ Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1.Title of Security
(Instr. 3)
2. Trans. Date 2A. Deemed Execution Date, if any 3. Trans. Code
(Instr. 8)
4. Securities Acquired (A) or Disposed of (D)
(Instr. 3, 4 and 5)
5. Amount of Securities Beneficially Owned Following Reported Transaction(s)
(Instr. 3 and 4)
6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V Amount (A) or (D) Price
Common Stock 5/16/2022  M(1)  10000 A$179.13 68470 D  
Common Stock 5/16/2022  F(1)  6457 D$648.31 62013 D  
Common Stock 5/17/2022  S(1)  59 D$655.4 61954 D  
Common Stock 5/17/2022  S(1)  58 D$656.52 61896 D  
Common Stock 5/17/2022  S(1)  60 D$657.51 61836 D  
Common Stock 5/17/2022  S(1)  123 D$658.56 61713 D  
Common Stock 5/17/2022  S(1)  77 D$660.32 (2)61636 D  
Common Stock 5/17/2022  S(1)  465 D$661.46 (3)61171 D  
Common Stock 5/17/2022  S(1)  779 D$662.57 (4)60392 D  
Common Stock 5/17/2022  S(1)  472 D$663.6 (5)59920 D  
Common Stock 5/17/2022  S(1)  428 D$664.32 (6)59492 D  
Common Stock 5/17/2022  S(1)  126 D$665.36 59366 D  
Common Stock 5/17/2022  S(1)  352 D$666.23 (7)59014 D  
Common Stock 5/17/2022  S(1)  154 D$667.49 (8)58860 D  
Common Stock 5/17/2022  S(1)  180 D$668.68 (9)58680 D  
Common Stock 5/17/2022  S(1)  153 D$669.12 (10)58527 D  
Common Stock 5/17/2022  S(1)  57 D$670.49 58470 D  
Common Stock         4285 I By 401(k) Plan 

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivate Security
(Instr. 3)
2. Conversion or Exercise Price of Derivative Security3. Trans. Date3A. Deemed Execution Date, if any4. Trans. Code
(Instr. 8)
5. Number of Derivative Securities Acquired (A) or Disposed of (D)
(Instr. 3, 4 and 5)
6. Date Exercisable and Expiration Date7. Title and Amount of Securities Underlying Derivative Security
(Instr. 3 and 4)
8. Price of Derivative Security
(Instr. 5)
9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)10. Ownership Form of Derivative Security: Direct (D) or Indirect (I) (Instr. 4)11. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeV(A)(D)Date ExercisableExpiration DateTitleAmount or Number of Shares
Non-Qualified Stock Option (right to buy) $179.13 5/16/2022  M (1)    10000   (11)12/14/2022 Common Stock 10000 $0.0 20000 D  

Explanation of Responses:
(1) Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c).
(2) Represents volume-weighted average price of sales of 77 shares of Company stock on May 17, 2022 at prices ranging from $660.18 to $660.72. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on May 17, 2022 at each separate price.
(3) Represents volume-weighted average price of sales of 465 shares of Company stock on May 17, 2022 at prices ranging from $661.16 to $661.93. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on May 17, 2022 at each separate price.
(4) Represents volume-weighted average price of sales of 779 shares of Company stock on May 17, 2022 at prices ranging from $662.29 to $662.89. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on May 17, 2022 at each separate price.
(5) Represents volume-weighted average price of sales of 472 shares of Company stock on May 17, 2022 at prices ranging from $663.20 to $663.80. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on May 17, 2022 at each separate price.
(6) Represents volume-weighted average price of sales of 428 shares of Company stock on May 17, 2022 at prices ranging from $664.01 to $664.80. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on May 17, 2022 at each separate price.
(7) Represents volume-weighted average price of sales of 352 shares of Company stock on May 17, 2022 at prices ranging from $666.11 to $666.93. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on May 17, 2022 at each separate price.
(8) Represents volume-weighted average price of sales of 154 shares of Company stock on May 17, 2022 at prices ranging from $667.27 to $667.86. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on May 17, 2022 at each separate price.
(9) Represents volume-weighted average price of sales of 180 shares of Company stock on May 17, 2022 at prices ranging from $668.41 to $668.88. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on May 17, 2022 at each separate price.
(10) Represents volume-weighted average price of sales of 153 shares of Company stock on May 17, 2022 at prices ranging from $669.00 to $669.21. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on May 17, 2022 at each separate price.
(11) The stock option award vests in four equal annual installments, commencing one year after the date of grant.

Reporting Owners
Reporting Owner Name / Address
Relationships
Director10% OwnerOfficerOther
MURPHY ANDREW J
777 OLD SAW MILL RIVER ROAD
TARRYTOWN, NY 10591


EVP Research

Signatures
/s/**Andrew Murphy5/17/2022
**Signature of Reporting PersonDate


Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
*If the form is filed by more than one reporting person, see Instruction 4(b)(v).
**Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note:File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.

1 Year Regeneron Pharmaceuticals Chart

1 Year Regeneron Pharmaceuticals Chart

1 Month Regeneron Pharmaceuticals Chart

1 Month Regeneron Pharmaceuticals Chart

Your Recent History

Delayed Upgrade Clock